{"entity":{"id":"nct04266249","kind":"trial","name":"CompassHER2-pCR","aka":["CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy"],"tldr":"CompassHER2-pCR tests whether people whose cancer clears with a shorter course of pre-surgery treatment can receive less chemotherapy afterward. Further treatment depends on what is found at surgery.","summary":"CompassHER2-pCR tests whether people whose cancer clears with a shorter course of pre-surgery treatment can receive less chemotherapy afterward. Further treatment depends on what is found at surgery.\n\nInterventional study registered as NCT04266249, sponsored by ECOG-ACRIN Cancer Research Group. Registry phase: 2. Registry enrollment is 2,175 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT04266249","url":"https://clinicaltrials.gov/study/NCT04266249"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT04266249"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["docetaxel","nab-paclitaxel","paclitaxel","pertuzumab","trastuzumab","trastuzumab-emtansine"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04266249","phase":"2","setting":"Early HER2-positive breast cancer treated before surgery","sponsor":"ECOG-ACRIN Cancer Research Group","participation":[{"nct":"NCT04266249","source":"https://clinicaltrials.gov/study/NCT04266249","fetchedAt":"2026-10-10T20:54:21.300658Z","studySha256":"52886fdaeaad30f26d8a77feb323192066ba77101dad13b42b398623dc0cc74d","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-14","leadSponsor":"ECOG-ACRIN Cancer Research Group","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":2175,"enrolmentType":"ACTUAL","siteCount":1008,"recruitingSiteCount":0,"countries":["Puerto Rico","United States"]}],"started":"2020-03-13","startedType":"actual","enrolled":2175,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04266249/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}